NCT04341675View on ClinicalTrials.gov

Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

July 15, 2020

Study Completion Date

September 15, 2020

Conditions
COVID-19
Interventions
DRUG

Sirolimus

Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.

DRUG

Placebo

Matching placebo

Trial Locations (2)

45267

University of Cincinnati, Cincinnati

60153

Loyola University Medical Center, Chicago

All Listed Sponsors
lead

University of Cincinnati

OTHER

NCT04341675 - Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter